A Phase 3 interventional study of Placebo and SM-13496 in Bipolar Depression, sponsored by Sumitomo Pharma Co., Ltd.. Completed at 8 sites in 8 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-04-12.
Sponsored by Sumitomo Pharma Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing lurasidone in Bipolar Disorder — 2 open to participants now, 2 under way, none of them phase 3. lurasidone · Bipolar Disorder.
Among the 17 studies testing lurasidone in Bipolar Disorder, this one is the 4th largest by enrollment, is one of 3 that started in 2014, is one of 11 in phase 3, and was the 10th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →2 of the 17 studies testing lurasidone in Bipolar Disorder are open now, in 2 countries. Recruiting first, the newest first:
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 16–65 · Healthy volunteers
Martin Lan · Sites in United States
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 525 is above the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 348 across the 17 interventional studies. Of the 14 that completed or were terminated, 12 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 9 most frequent:
Sumitomo Pharma Co., Ltd. is the lead sponsor of 25 studies on the registry; none are open to participants now.
Sumitomo Pharma Co., Ltd. has 9 studies filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
1 of the studies testing lurasidone in Bipolar Disorder that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05480150First Affiliated Hospital of Zhejiang UniversityChinese Longitudinal and Systematic Study of Bioplar Disorder | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing lurasidone in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with Bipolar I Depression.
The primary objective is to compare the efficacy of SM-13496 (20-60 or 80-120 mg/day) monotherapy with that of placebo in patients with depressive symptoms associated with bipolar I disorder by assessing the change from baseline in the MADRS total score at Week 6.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
once daily orally
Drug: Placebo
once daily orally
Drug: SM-13496
once daily orally
Drug: SM-13496
Placebo comparator
SM-13496 20mg for Days 1-7 and beginning Day 8 flexibly dosed 20-60 mg/day for Weeks 2-6
Also known as: Lurasidone HCl
SM-13496 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6, 80 mg/day on Day 7 and beginning Day 8 flexibly dosed 80-120 mg/day for Weeks 2-6
Also known as: Lurasidone HCl
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6
Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression. The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.
Time frame: Baseline to 6 weeks
Change From Baseline in the CGI-BP-S (Depression) Score at Week 6
Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) is a clinician-rated assessment of a subject's level of depression. The CGI depression score ranges from a minimum of 1 to a maximum of 7. For the CGI depression score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.
Time frame: Baseline to 6 weeks
Change From Baseline in the SDS Total Score at Week 6 (LOCF)
Sheehan Disability Scale (SDS) total score is a subject-rated assessment of a subject's level of functional impairment in work/school, social life and family life/home responsibilities. The SDS total score ranges from a minimum of 0 to a maximum of 30. For the SDS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The SDS contains three (3) items. The total score is computed as the sum of the scores for the 3 items.
Time frame: Baseline to 6 weeks
Change From Baseline in the YMRS Total Score at Week 6
YMRS (Young Mania Rating Scale) is a clinician-rated assessment of the severity of mania in subjects with a diagnosis of bipolar disorder. The YMRS total score ranges from a minimum of 0 to a maximum of 60. For the YMRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The YMRS contains eleven (11) items. The total score is computed as the sum of the scores for the 11 items.
Time frame: Baseline to 6 weeks
Change From Baseline in the HAM-A Total Score at Week 6 (LOCF)
The Hamilton Rating Scale for Anxiety (HAM-A) scale is a rating scale developed to quantify the severity of anxiety symptomatology. The HAM-A total score ranges from a minimum of 0 to a maximum of 56. For the HAM-A total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The HAM-A contains fourteen (14) items. The total score is computed as the sum of the scores for the 14 items.
Time frame: Baseline to 6 weeks
| Milestone | Placebo | SM-13496 20 - 60 mg/Day | SM-13496 80 - 120 mg/Day |
|---|---|---|---|
| Started | 172 | 184 | 169 |
| Intent-to-treat population | 171 | 182 | 169 |
| Safety population | 172 | 184 | 169 |
| Completed | 139 | 157 | 137 |
| Not completed | 33 | 27 | 32 |
Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression. The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.
| units on a scale | Placebo | SM-13496 20 - 60 mg/Day | SM-13496 80 - 120 mg/Day |
|---|---|---|---|
| Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 | -10.6 ± 0.72 | -13.6 ± 0.69 | -12.6 ± 0.73 |
Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) is a clinician-rated assessment of a subject's level of depression. The CGI depression score ranges from a minimum of 1 to a maximum of 7. For the CGI depression score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.
| units on a scale | Placebo | SM-13496 20 - 60 mg/Day | SM-13496 80 - 120 mg/Day |
|---|---|---|---|
| Change From Baseline in the CGI-BP-S (Depression) Score at Week 6 | -1.11 ± 0.092 | -1.51 ± 0.088 | -1.41 ± 0.093 |
Sheehan Disability Scale (SDS) total score is a subject-rated assessment of a subject's level of functional impairment in work/school, social life and family life/home responsibilities. The SDS total score ranges from a minimum of 0 to a maximum of 30. For the SDS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The SDS contains three (3) items. The total score is computed as the sum of the scores for the 3 items.
| units on a scale | Placebo | SM-13496 20 - 60 mg/Day | SM-13496 80 - 120 mg/Day |
|---|---|---|---|
| Change From Baseline in the SDS Total Score at Week 6 (LOCF) | -5.7 ± 0.66 | -7.6 ± 0.62 | -6.8 ± 0.67 |
YMRS (Young Mania Rating Scale) is a clinician-rated assessment of the severity of mania in subjects with a diagnosis of bipolar disorder. The YMRS total score ranges from a minimum of 0 to a maximum of 60. For the YMRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The YMRS contains eleven (11) items. The total score is computed as the sum of the scores for the 11 items.
| units on a scale | Placebo | SM-13496 20 - 60 mg/Day | SM-13496 80 - 120 mg/Day |
|---|---|---|---|
| Change From Baseline in the YMRS Total Score at Week 6 | -0.51 ± 0.190 | -0.98 ± 0.180 | -0.99 ± 0.191 |
The Hamilton Rating Scale for Anxiety (HAM-A) scale is a rating scale developed to quantify the severity of anxiety symptomatology. The HAM-A total score ranges from a minimum of 0 to a maximum of 56. For the HAM-A total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The HAM-A contains fourteen (14) items. The total score is computed as the sum of the scores for the 14 items.
| units on a scale | Placebo | SM-13496 20 - 60 mg/Day | SM-13496 80 - 120 mg/Day |
|---|---|---|---|
| Change From Baseline in the HAM-A Total Score at Week 6 (LOCF) | -5.7 ± 0.51 | -7.4 ± 0.49 | -6.4 ± 0.50 |
Collected over 6 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/172 (0%) | 5/172 (2.9%) | 44/172 (25.6%) |
| SM-13496 20 - 60 mg/Day | 0/184 (0%) | 2/184 (1.1%) | 49/184 (26.6%) |
| SM-13496 80 - 120 mg/Day | 0/169 (0%) | 4/169 (2.4%) | 75/169 (44.4%) |
| Event | Placebo | SM-13496 20 - 60 mg/Day | SM-13496 80 - 120 mg/Day |
|---|---|---|---|
| Disease progressionGeneral disorders | 1/172 | 0/184 | 1/169 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/172 | 0/184 | 1/169 |
| Panic attackPsychiatric disorders | 0/172 | 0/184 | 1/169 |
| Suicide attemptPsychiatric disorders | 0/172 | 0/184 | 1/169 |
| Acute myocardial infarctionCardiac disorders | 1/172 | 0/184 | 0/169 |
| Abdominal painGastrointestinal disorders | 1/172 | 0/184 | 0/169 |
| Bipolar I disorderPsychiatric disorders | 1/172 | 0/184 | 0/169 |
| ManiaPsychiatric disorders | 1/172 | 1/184 | 0/169 |
| Suicidal ideationPsychiatric disorders | 0/172 | 1/184 | 0/169 |
| Event | Placebo | SM-13496 20 - 60 mg/Day | SM-13496 80 - 120 mg/Day |
|---|---|---|---|
| AkathisiaNervous system disorders | 11/172 | 24/184 | 40/169 |
| NauseaGastrointestinal disorders | 10/172 | 12/184 | 20/169 |
| HeadacheNervous system disorders | 15/172 | 5/184 | 9/169 |
| SomnolenceNervous system disorders | 7/172 | 7/184 | 11/169 |
| ParkinsonismNervous system disorders | 4/172 | 4/184 | 10/169 |
| NasopharyngitisInfections and infestations | 8/172 | 10/184 | 6/169 |
Intention-to-treat population is analyzed.
| Age, Continuous(years) | Placebo | SM-13496 20 - 60 mg/Day | SM-13496 80 - 120 mg/Day | Total |
|---|---|---|---|---|
| Mean | 41.3 ± 12.64 | 42.6 ± 12.86 | 43.2 ± 12.78 | 42.4 ± 12.77 |
| Sex: Female, Male(Participants) | Placebo | SM-13496 20 - 60 mg/Day | SM-13496 80 - 120 mg/Day | Total |
|---|---|---|---|---|
| Female | 94 | 95 | 88 | 277 |
| Male | 77 | 87 | 81 | 245 |
| Race/Ethnicity, Customized(Participants) | Placebo | SM-13496 20 - 60 mg/Day | SM-13496 80 - 120 mg/Day | Total |
|---|---|---|---|---|
| White | 94 | 105 | 103 | 302 |
| Asian | 77 | 77 | 66 | 220 |
| Region of Enrollment(Participants) | Placebo | SM-13496 20 - 60 mg/Day | SM-13496 80 - 120 mg/Day | Total |
|---|---|---|---|---|
| Japan | 60 | 65 | 53 | 178 |
| Philippines | 5 | 3 | 3 | 11 |
| Taiwan | 5 | 3 | 4 | 12 |
| Ukraine | 43 | 43 | 45 | 131 |
| Malaysia | 7 | 6 | 6 | 19 |
| Slovakia | 5 | 7 | 4 | 16 |
| Lithuania | 2 | 4 | 4 | 10 |
| Russia | 44 | 51 | 50 | 145 |
| Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score(units on a scale) | Placebo | SM-13496 20 - 60 mg/Day | SM-13496 80 - 120 mg/Day | Total |
|---|---|---|---|---|
| Mean | 30.9 ± 5.39 | 30.6 ± 5.57 | 30.8 ± 5.09 | 30.8 ± 5.35 |
| Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)(units on a scale) | Placebo | SM-13496 20 - 60 mg/Day | SM-13496 80 - 120 mg/Day | Total |
|---|---|---|---|---|
| Mean | 4.60 ± 0.690 | 4.57 ± 0.700 | 4.58 ± 0.603 | 4.58 ± 0.666 |
| Sheehan Disability Scale (SDS) total score(units on a scale) | Placebo | SM-13496 20 - 60 mg/Day | SM-13496 80 - 120 mg/Day | Total |
|---|---|---|---|---|
| Mean | 19.9 ± 5.22 | 19.4 ± 5.29 | 19.8 ± 5.58 | 19.7 ± 5.35 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Feb 2014 to primary completion in Feb 2017, 35 months.
Results were first posted in Jul 2019, 2 years 5 months after primary completion.
Of 29 industry-sponsored phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 35 months is close to that.
Counting every sponsor, half of 43 studies reached it within 37 months; a quarter within 21 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone